S. 1505Senate116th Congress (2019-2021)In Committee

Medicare Prescription Drug Fraud Prevention Act of 2019

AI-Generated Summary

Updated April 14, 2026 at 5:16 AM UTC

The Medicare Prescription Drug Fraud Prevention Act of 2019 would make sponsors of Medicare prescription drug plans and Medicare Advantage‑Prescription Drug (MA‑PD) plans report any suspected or confirmed fraud, waste, or abuse in the Part D program to the Secretary of Health and Human Services. The reporting requirement would start on January 1, 2021 and would also require sponsors to describe any corrective steps they take.

Key Provisions

Amends the Social Security Act to add a new reporting requirement (subsection (o)) for prescription drug plan sponsors.
Requires sponsors to report any substantiated or suspicious fraud, waste, or abuse activities to the HHS Secretary, as defined by the Secretary.
Mandates that sponsors also report any corrective actions they have taken after identifying such activities.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action

SenateIntro Referral Latest Action

Read twice and referred to the Committee on Finance.

Finance Committee

May 16, 2019

View full timeline

SenateIntro Referral

Introduced in Senate

May 16, 2019

SenateIntro Referral

Read twice and referred to the Committee on Finance.

Finance Committee

May 16, 2019

Bill Text

Latest available legislative text

Reading Mode

Raw Text PDF XML

Introduced in SenateIssued May 16, 2019

116th CONGRESS

1st Session

S. 1505

IN THE SENATE OF THE UNITED STATES

May 16, 2019

Mr. Cornyn (for himself and Mr. Cardin) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To require prescription drug plans and MA–PD plans to report potential fraud, waste, and abuse to the Secretary of Health and Human Services under Medicare part D, and for other purposes.

Short title

This Act may be cited as the Medicare Prescription Drug Fraud Prevention Act of 2019.

Requiring prescription drug plans and MA–PD plans to report potential fraud, waste, and abuse to the Secretary of HHS

Section 1860D–4 of the Social Security Act (42 U.S.C. 1395w–104) is amended—

(1)

by redesignating subsection (m) (relating to program integrity transparency measures), as added by section 6063(c) of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (Public Law 115–271), as subsection (n); and

(2)

by adding at the end the following new subsection:

(o)

Reporting potential fraud, waste, and abuse

Beginning January 1, 2021, the PDP sponsor of a prescription drug plan shall report to the Secretary, as specified by the Secretary—

(1)

any substantiated or suspicious activities (as defined by the Secretary) with respect to the program under this part as it relates to fraud, waste, and abuse; and

(2)

any steps made by the PDP sponsor after identifying such activities to take corrective actions.